NEW YORK (Reuters Health) – In patients with moderate-severe COVID-19, recombinant super-compound interferon (rSIFN-co) plus baseline antivirals was associated with a shorter time to clinical improvement...

The common cold virus could offer some level of protection against COVID-19 infection, according to a new study. The research—published today in Journal of Infectious Diseases and led by scientists...

LONDON (Reuters) – Confidence in the safety of AstraZeneca’s COVID-19 vaccine has taken a big hit in Spain, Germany, France and Italy as reports of rare blood clots have been linked to it and...

COPENHAGEN (Reuters) – Denmark said on Saturday that one person had died and another fell seriously ill with blood clots and cerebral haemorrhage after receiving the AstraZeneca COVID-19 vaccination. The...

COPENHAGEN/OSLO/STOCKHOLM (Reuters) – Denmark, Sweden and Norway said on Friday they needed more time to decide whether to use AstraZeneca’s COVID-19 vaccine even though the EU drug watchdog...

Some patients with moderate to severe COVID-19 disease seem to experience inflammation of the thyroid gland that is different from thyroid inflammation caused by other viruses, according to a study presented...

People in prisons are at an increased risk of COVID-19—with a death rate over three times higher than that of the general population—and should be made a vaccine priority, according to UCL-led team...

Fewer than 1% of COVID-19 survivors are reinfected with the virus – but those aged 65 or older are nearly 50% more likely to get the disease twice compared to younger people, new study finds Researchers looked...

(Reuters Health) – The AstraZeneca COVID-19 vaccine developed with the University of Oxford has an efficacy of only 10.4% against the South African variant of the virus, according to data published...

(Reuters) – Canadian drug developer Medicago said on Tuesday it had started a late-stage study of its experimental COVID-19 vaccine combined with an adjuvant from GlaxoSmithKline. The study plans...